KEYNOTE-B96 Brings Immunotherapy-Based Option to Platinum-Resistant Ovarian Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
KEYNOTE-B96 Brings Immunotherapy-Based Option to …
1 month ago
targetedonc.com
KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC
KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC
Jul 12, 2022
vjoncology.com
KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervi…
Sep 19, 2021
ascopost.com
IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCLC | CancerNetwork
IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCL…
May 13, 2022
cancernetwork.com
KEYNOTE-091 Evaluates Adjuvant Pembrolizumab in Resected Early-Stage NSCLC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
KEYNOTE-091 Evaluates Adjuvant Pembrolizumab in Resected Early …
Jul 19, 2022
targetedonc.com
Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies | OncLive
Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 S…
Jul 13, 2023
onclive.com
KEYNOTE-811: Clinical Outcomes and Safety of Pembrolizumab Trastuzumab Chemotherapy in HER2-Positive Gastric/GEJ Adenocarcinoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
KEYNOTE-811: Clinical Outcomes and Safety of Pembrolizumab Tras…
5 months ago
targetedonc.com
Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial i…
Jun 26, 2023
onclive.com
Pembrolizumab Alone or Combined With Chemotherapy vs Chemother…
Sep 27, 2022
urotoday.com
14:04
EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enf…
Oct 31, 2023
onclive.com
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pe…
Jan 25, 2023
marketscreener.com
1:55
Watch Peter Schmid, MD, PhD, FRCP, of Barts Cancer Insitute dis…
55 viewsDec 4, 2024
FacebookOncLive
ASCO® 2023 Insights: "KEYNOTE-859 Study of Pembro Chemo for A…
Jul 13, 2023
vumedi.com
Dr. Monk on Transformative KEYNOTE-826 Data in Frontline C…
Sep 18, 2021
onclive.com
5:36
Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy i…
Oct 28, 2024
onclive.com
Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 - Pem…
20 viewsSep 14, 2022
touchoncology.com
Merck Announces Phase 3 KEYNOTE-811 trial Investigating K…
Jun 16, 2023
marketscreener.com
Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head …
Aug 20, 2020
onclive.com
Dr. Reck on the Safety of Pembrolizumab in KEYNOTE-024 i…
Sep 30, 2020
onclive.com
3:55
Why Do Gastric Cancer Immunotherapy Outcomes Differ b…
1 month ago
YouTubeFunniest Internet Clips
21:40
How to Treat Biliary Tract Cancer – Treatment Algorithm with Dr. Sun…
590 views1 month ago
YouTubeOncBrothers: Practice-Changing Cancer Discus…
3:01
Choosing Between Atezolizumab and Pembrolizumab in Lung Cancer
6.7K viewsJul 2, 2018
YouTubeTargeted Oncology
20:05
Beginner's Guide to Apple Keynote
498.1K viewsJul 15, 2019
YouTubeTechnology for Teachers and Students
10:09
ESMO 2020 Expert Video Report on long term ICI outcomes in lung ca…
1.1K viewsSep 30, 2020
YouTubeEuropean Society for Medical Oncology (ESMO)
30:53
Immunotherapy Side Effects: What Patients Need to Know with Dr. Je…
117.7K viewsSep 9, 2020
YouTubeCancer Research Institute
34:48
📖 Complete Beginner's Guide to Apple Keynote
334.2K viewsApr 23, 2020
YouTubeVideoPlasty
5:53
Martin Reck:
1.2K viewsOct 9, 2016
YouTubeOncoletter
14:45
Keytruda plus chemotherapy (KEYNOTE 189, KEYNOTE 407)
20.5K viewsAug 15, 2021
YouTube呼吸器ドクターNの肺がんチャンネル
6:40
Chemotherapy/Immunotherapy Combinations in Lung Cancer
2K viewsJun 16, 2017
YouTubeOncLive
3:34
Sequencing Immunotherapy in Advanced-Stage Lung Cancer
178 viewsJan 15, 2018
YouTubeTargeted Oncology
See more videos
Static thumbnail place holder